Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWD
Ironwood Pharmaceuticals — Q3 2025 Earnings Presentation
14 slides from Ironwood Pharmaceuticals's earnings presentation, Nov 10, 2025
Slide 1: Q3 2025 Investor Update
Ironwood Pharmaceuticals Q3 2025 Investor Update November 10, 2025 1 
Slide 2: Safe harbor statement
Safe harbor statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our mi
Slide 3: Strong third quarter execution across our strategic priorities
Strong third quarter execution across our strategic priorities Advancing Apraglutide ▪ Plan to align with the FDA in Q4’25 on confirmatory Phase 3 trial design, and pending alignment expect to initiate trial in 1H’26 Maximizing LINZESS ▪ Delivered strong Q3 LINZESS U.S. net sales of $315 million, a
Slide 4: LINZESS EUTRx and NBRx prescriptions each grew 12% year-over-year in Q3 2025
LINZESS extended unit (EUTRx) and new to brand (NBRx) prescriptions each grew 12% year-over-year in Q3 2025 LINZESS Monthly EUTRx LINZESS Monthly NBRx 22,000,000 +12% 70,000 +12% Q3'25 Y/Y Q3'25 Y/Y 20,000,000 52,500 18,000,000 EUTRx Volume NBRx Volume 16,000,000 35,000 14,000,000 17,500 12,000,000
Slide 5: Q3 2025 financial summary
Q3 2025 financial summary LINZESS U.S. Brand Collaboration Commercial Profit & Collaboration Revenue1 Three Months Ended Nine Months Ended Sept 30, 2025 Sept 30, 2025 (000s) (000s) LINZESS U.S. net product sales as reported by AbbVie2 $ 314,856 $ 701,334 AbbVie & Ironwood commercial costs, expenses
Slide 6: Q3 2025 financial performance
Q3 2025 financial performance $315M $122M LINZESS U.S. Net Sales1 Total Ironwood Revenues Q3 2025 LINZESS net sales as reported by AbbVie were Primarily driven by $120M in U.S. LINZESS $315M, up 40% year-over-year, driven by improved net collaboration revenue pricing2 and strong demand growth of 12%
Slide 7: We are raising our FY 2025 guidance based on strong prescription demand growth
We are raising our FY 2025 guidance based on strong prescription demand growth of LINZESS and improved net pricing year-to-date Previous FY 2025 Revised FY 2025 Guidance Guidance (August 2025) (November 2025) LINZESS U.S. net sales $800 – $850 million $860 – $890 million Total revenue $260 – $290 mi
Slide 8: Appendix
APPENDIX \\ Ironwood!
Slide 9: Reconciliation of GAAP results to non-GAAP financial measures (page 1)
Q3 2025 financial summary Reconciliation of GAAP results to non-GAAP financial measures (page 1) Three Months Ended Nine Months Ended Sept 30, 2025 Sept 30, 2025 (000s, except per share (000s, except per share amounts) amounts) GAAP net income1 $ 40,080 $ 26,293 Adjustments: Amortization of acquired
Slide 10: Reconciliation of GAAP results to non-GAAP financial measures (page 2)
Q3 2025 financial summary Reconciliation of GAAP results to non-GAAP financial measures (page 2) Three Months Ended Nine Months Ended Sept 30, 2025 Sept 30, 2025 (000s, except per share (000s, except per share amounts) amounts) GAAP net income per share – diluted1 $ 0.23 $ 0.16 Adjustments to GAAP n
Slide 11: Reconciliation of GAAP net income to adjusted EBITDA
Q3 2025 financial summary Reconciliation of GAAP net income to adjusted EBITDA Three Months Ended Nine Months Ended Sept 30, 2025 Sept 30, 2025 (000s) (000s) GAAP net income1 $ 40,080 $ 26,293 Adjustments: Stock-based compensation 3,612 13,427 Restructuring expenses 2,200 20,509 Interest expense 8,4
Slide 12: Q3 2025 vs. Q3 2024
Q3 2025 vs. Q3 2024 LINZESS U.S. Brand Collaboration Commercial Profit & Collaboration Revenue1 Three Months Ended Three Months Ended Sept 30, 2025 Sept 30, 2024 (000s) (000s) LINZESS U.S. net product sales as reported by AbbVie2 $ 314,856 $ 225,537 AbbVie & Ironwood commercial costs, expenses and o
Slide 13: Ironwood & AbbVie Total Net Profit
Q3 2025 financial summary LINZESS U.S. Brand Collaboration Ironwood & AbbVie Total Net Profit1 Three Months Ended Nine Months Ended Sept 30, 2025 Sept 30, 2025 (000s) (000s) LINZESS U.S. net sales as reported by AbbVie2 $ 314,856 $ 701,334 AbbVie & Ironwood commercial costs, expenses and other 75,82
Slide 14: Thank You
AThank You
Ironwood Pharmaceuticals — Q3 2025 Earnings Presentation on 6ix